11.86

1.77% -0.16

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $11.86, with a volume of 152.82K. It is down -1.77% in the last 24 hours and up +2.14% over the past month. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Previous Close:

$12.02

Open:

$12.08

24h Volume:

152.82K

Relative Volume:

0.25

Market Cap:

$816.44M

Revenue:

Net Income/Loss:

$-209.96M

P/E Ratio:

-3.9933

EPS:

-2.97

Net Cash Flow:

$-176.27M

1W Performance:

-3.85%

1M Performance:

+2.14%

6M Performance:

+69.88%

1Y Performance:

-16.85%

1-Day Range:

$11.72

$12.33

1-Week Range:

$11.22

$12.37

52-Week Range:

$4.92

$14.72

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

331

Twitter

@Replimune

Next Earnings Date

2024-11-05

Latest SEC Filings

REPL's Discussions on Twitter

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

04:17 AM

Vanguard Group's Strategic Acquisition in Replimune Group Inc - GuruFocus.com

04:17 AM

Oct 30, 2024

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - The Manila Times

Oct 30, 2024

Oct 23, 2024

Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Oct 23, 2024

Oct 22, 2024

SG Americas Securities LLC Invests $251,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Oct 22, 2024

Oct 18, 2024

Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Oct 18, 2024

Oct 16, 2024

It would be worthwhile to take a closer look at Replimune Group Inc (REPL) - US Post News

Oct 16, 2024

Oct 15, 2024

Daily Progress: Replimune Group Inc (REPL) Drop -7.06, Closing at 10.67 - The Dwinnex

Oct 15, 2024